Dinutuximab

Category: Cancer



Dinutuximab Overview

Dinutuximab (Ch14.18, tradename Unituxin) and Dinutuximab beta (tradename Isquette) is a monoclonal antibody used as a second-line treatment for children with high-risk neuroblastoma. Each antibody is made of both mouse and human components and targets glycolipid GD2, expressed on neuroblastoma cells and on normal cells of neuroectodermal origin, including the central nervous system and peripheral nerves. They differ in that dinutuximab is manufactured using mouse cells, and dinutuximab bet...

Read more Dinutuximab Details
Details May Include Instructions, Side Effects, Interactions, Etc. Drug monograph is from Wikipedia. All text is available under the terms of the GFDL (GNU Free Documentation License). Source: en.wikipedia.org/wiki/Dinutuximab

Recent Dinutuximab Forums:

Be the first to start a discussion about this drug.

Possible Dosages for this and Related Drugs:

Dinutuximab
  • Injection: 17.5mg/5ml
Note: Above list includes dosages for all drugs with the same combination of active ingredients.

Other drugs which contain Dinutuximab or a similar ingredient: (1 result)






Note: All times displayed are GMT - 7.

This information has been independently compiled and is for informational purposes only. It is not intended to be a substitute for medical advice from a qualified healthcare professional; nor is it intended to diagnose, treat, cure or prevent any disease. For more details please see the Medical Disclaimer. This page was last updated on 18 March 2019.

We are committed to your privacy.

Copyright © 2005-2019 All Rights Reserved. MedsChat® is a registered trademark of Limelight Innovations L.L.C. 9888 W Belleview Ave #5000, Denver, CO, 80123, USA